OBJECTIVE： To observe clinical efficacy and safety of Salvia tetramethylpyrazine injection combined with  trimetazidinein the treatment of acute phase of viral myocarditis. METHODS： 110 patients with acute phase of viral myocarditis were divided into control group and observation group according to random number table， with 55 cases in each group. Both groups received basic treatment as fructose sodium dipllosphate， high-protein diet. Control group was given Trimetazidine hydrochloride tablet 20 mg， po， tid； observation group was additionally given Salvia tetramethylpyrazine injection 5 ml added into 5％ Glucose injection 250 ml， ivgtt， qd. Both groups received treatment for consecutive 30 d. The clinical efficacy and therapeutic efficacy of electrocardiogram S-T segment were compared between 2 groups. The levels of serum inflammatory factors （IL-6， hs-CRP）， oxidative stress factors （MDA， SOD），  cardiac enzymes （CK， LDH） and the occurrence of ADR were compared between 2 groups before and after treatment. RESULTS： The total effective rate and total effective rate of electrocardiogram S-T segment in observation group were 94.5％ and 90.9％， which was significantly higher than those of control group （85.4％ and. 81.8％）， with statistical significance （P＜0.05）. There was no statistical significance in the levels of IL-6， hs-CRP， MDA， SOD， CK and LDH between 2 groups before treatment （P＞0.05）. After treatment， the levels of IL-6， hs-CRP， MDA， SOD， CK and LDH were decreased significantly in 2 groups， while MDA was significantly increased； the observation group was significantly better than the control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Salvia tetramethylpyrazine injection combined with trimetazidine is effective in the treatment of acute phase of viral myocarditis， can effectively improve electrocardiogram and lab indexes with good safety.